Tango Therapeutics Inc (NASDAQ:TNGX) — Market Cap & Net Worth
Market Cap & Net Worth: Tango Therapeutics Inc (TNGX)
Tango Therapeutics Inc (NASDAQ:TNGX) has a market capitalization of $4.14 Billion ($4.14 Billion) as of September 16, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #4031 globally and #1412 in its home market, demonstrating a 7.82% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Tango Therapeutics Inc's stock price $24.54 by its total outstanding shares 168610367 (168.61 Million). Also see TNGX total asset value for a full breakdown of the balance sheet.
Tango Therapeutics Inc Market Cap History: 2020 to 2026
Tango Therapeutics Inc's market capitalization history from 2020 to 2026. Data shows growth from $1.93 Billion to $4.14 Billion (15.61% CAGR). Also see Tango Therapeutics Inc cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Tango Therapeutics Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.68 Trillion | 0.15% | #101 of 976 |
|
NASDAQ Composite
IXIC
|
$41.94 Trillion | 0.01% | #469 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.89 Trillion | 0.22% | #66 of 263 |
Weight: Tango Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Tango Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Tango Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check TNGX stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
23.95x
Tango Therapeutics Inc's market cap is 23.95 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $1.93 Billion | $7.66 Million | -$51.97 Million | 251.95x | N/A |
| 2021 | $1.84 Billion | $37.04 Million | -$58.23 Million | 49.80x | N/A |
| 2022 | $1.22 Billion | $24.86 Million | -$108.18 Million | 49.17x | N/A |
| 2023 | $1.67 Billion | $36.53 Million | -$101.74 Million | 45.70x | N/A |
| 2024 | $521.01 Million | $42.07 Million | -$130.30 Million | 12.38x | N/A |
| 2025 | $1.49 Billion | $62.38 Million | -$101.59 Million | 23.95x | N/A |
Competitor Companies of TNGX by Market Capitalization
Companies near Tango Therapeutics Inc in the global market cap rankings as of September 16, 2026. Review TNGX tangible net assets ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Tango Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #338 globally with a market cap of $80.28 Billion USD.
- CSL Ltd (AU:CSL): Ranked #463 globally with a market cap of $58.90 Billion USD ( AU$83.24 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #509 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $519.51 |
| #338 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $80.28 Billion | $793.74 |
| #463 | CSL Ltd | AU:CSL | $58.90 Billion | AU$171.57 |
| #509 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $146.69 |
Tango Therapeutics Inc Historical Marketcap From 2020 to 2026
Between 2020 and today, Tango Therapeutics Inc's market cap moved from $1.93 Billion to $ 4.14 Billion, with a yearly change of 15.61%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $4.14 Billion | +176.98% |
| 2025 | $1.49 Billion | +186.73% |
| 2024 | $521.01 Million | -68.79% |
| 2023 | $1.67 Billion | +36.55% |
| 2022 | $1.22 Billion | -33.73% |
| 2021 | $1.84 Billion | -4.37% |
| 2020 | $1.93 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 15th, 2026 the market cap of Tango Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.14 Billion USD |
| MoneyControl | $4.14 Billion USD |
| MarketWatch | $4.14 Billion USD |
| marketcap.company | $4.14 Billion USD |
| Reuters | $4.14 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Tango Therapeutics Inc
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant … Read more